A Real-World Study of β-Thalassemia Major Treatment With Luspatercept in Taiwan
← catalyst calendarNCT06596642 · readout in 43 d
Sponsored by Bristol-Myers Squibb (industry) · BMY — their whole pipeline →.
Phase
—
Status
Active, not recruiting
Study type
Observational
Enrollment
61actual
Sites
5
Country
Taiwan
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-08-21 | actual | When the study began enrolling |
| Primary completion | 2026-10-01 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-12-17 | estimated | The whole study's end, after follow-up |
| First posted | 2024-09-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2025-06-04 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- β-Thalassemia Major
Intervention
- Drug: Luspatercept
Primary outcomes
what the primary-completion date above is the date OFNumber of Red Blood Cell (RBC) transfusion units received by participants
measured Baseline, every 3 weeks thereafter until week 96
Participant hemoglobin (Hb) level results
measured Baseline, every 3 weeks thereafter until week 96
Participant serum ferritin results
measured Baseline, week 12, 24, 36, 48, 60, 72, 84 and 96
Permalink · BMY's whole pipeline · Catalyst calendar · Every registered study · What changed